Inflammasome-Related Genetic Polymorphisms as Severity Biomarkers of COVID-19

Area of Science:

• Immunology
• Genetics
• Infectious Diseases

Background:

• Excessive inflammasome activation is linked to critical COVID-19.
• Understanding the inflammasome's role in disease severity is crucial for public health.
• Mechanisms linking inflammatory responses to COVID-19 prognosis require further elucidation.

Purpose of the Study:

• To investigate the association between inflammasome-related gene polymorphisms and COVID-19 severity.
• To identify potential genetic biomarkers for predicting COVID-19 disease progression.
• To analyze the role of specific inflammasome pathway gene variants in patient outcomes.

Main Methods:

• Genotyping of 24 polymorphisms in key inflammasome genes (e.g., NLRP3, CASP1, IL1B) using RT-qPCR.
• Analysis of a cohort including 377 COVID-19 patients across mild, moderate, severe, and critical illness categories.
• Comparison of genetic and allelic distributions between COVID-19 patients and 192 healthy controls.

Main Results:

• No statistically significant differences in allelic or genotypic distributions were found across all studied variants in COVID-19 patients stratified by severity.
• Haplotype distributions for inflammasome genes (NLRP3, NLRC4, NLRP1, CARD8, CASP1, IL1B, ATG16L1) showed no significant variation between severity groups.
• Genetic distributions in all patient groups mirrored those observed in healthy controls.

Conclusions:

• The studied inflammasome gene polymorphisms are not associated with COVID-19 severity.
• These genetic variants do not serve as reliable biomarkers for predicting the progression or critical outcomes of coronavirus disease 2019.
• Further research may be needed to explore other genetic or non-genetic factors influencing COVID-19 prognosis.